[Characteristics of "Avaxim" hepatitis A vaccine produced by the firm "Pasteur Merrier" (results of field clinical trials)].
Controlled field clinical trials of Avaxim vaccine from hepatitis A (Pasteur-Merrier-Connot) were carried out in adults and children aged 3-14 years to evaluate its reactogenicity and antigenic properties. The vaccine was weakly reactogenic both in adults and children. A single injection of the vaccine resulted after 1 month in the production of anti-HAV antibodies in 77.4% initially seronegative adults and 94.5% children. In adults the mean geometrical titer of antibodies was 95 mIU/ml and in children 165 mIU/ml, which was 5-8 times higher than the protective titer. These data recommend Avaxim vaccine for practical public health.
Gorbunov
M A
MA
Noskova
A V
AV
El'shina
G A
GA
Bektimirov
T A
TA
Pavlova
L I
LI
Aksenov
L A
LA
Ivanov
A A
AA
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D002648:Child; D002675:Child, Preschool; D022362:Hepatitis A Vaccines; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D022362:Hepatitis A Vaccines; D014761:Viral Hepatitis Vaccines